Review Article

Neoplastic Bone Marrow Niche: Hematopoietic and Mesenchymal Stem Cells

Najmaldin Saki, M.Sc.¹,², Saeid Abroun, Ph.D.¹*, Majid Farshdousti Hagh, Ph.D.³, Farahnaz Asgharei, Ph.D.⁴

¹. Department of Hematology and Blood Banking School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
². Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
³. Department of Hematology, Tabriz University of Medical Sciences, Tabriz, Iran
⁴. Department of Immunogenetic, Rostok University, Rostok, Germany

* Corresponding Address: P.O.Box:14115-331, Department of Hematology and Blood Banking School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Email: abroun@modares.ac.ir

Received:20/Jun/2011, Accepted:18/Aug/2011

Abstract

The neoplastic niche comprises complex interactions between multiple cell types and molecules requiring cell-cell signaling as well as local secretion. These niches are important for both the maintenance of cancer stem cells and the induction of neoplastic cells survival and proliferation. Each niche contains a population of tumor stem cells supported by a closely associated vascular bed comprising mesenchyme-derived cells and extracellular matrix. Targeting cancer stem cells and neoplastic niche may provide new therapies to eradicate tumors. Much progress has been very recently made in the understanding of the cellular and molecular interactions in the microenvironment of neoplastic niches. This review article provides an overview of the neoplastic niches in the bone marrow. In addition to highlighting recent advances in the field, we will also discuss components of the niche and their signaling pathways.

Keywords: Neoplastic Niche, Stem Cells, Bone Marrow, Cancer

Table 1: Cell-derived hematopoietic and mesenchymal stem cells

| Hematopoietic stem cells | Common lymphoid progenitor | B Cells | T Cells | NK Cells |
|--------------------------|----------------------------|---------|---------|----------|
|                          |                            | Granulocyte-Macrophage progenitors | Granulocyte | Monocyte | Macrophage | Osteoclast |
| Mesenchymal stem cells   | Common myeloid progenitor | Megakaryocyte-Erythroid progenitors | Megakaryocyte | Erythrocyte |
|                          | Chondrocyte, Osteoblast, Fibroblast, Adipocyte, Myocyte, Endothelial cells |

Introduction

Bone marrow microenvironment contains stem cells and other cells that are supported by hematopoietic and mesenchymal stem cells (MSCs). These cells can differentiate into several cell lineages (Table 1). Osteoclasts and osteoblasts play important role in microenvironment destruction and construction (1). Osteoblasts derive from MSCs that play an important role in the construction of Osteoblastic/endosteal niches. Osteoblastic niches maintain hematopoietic stem cells (HSCs) in quiescence phase (2). Cancer initiating cells disrupt cell-cell and cell-matrix interactions in the bone marrow. Therefore, they can change intact niches into neoplastic niches. Therefore, the bone marrow microenvironment plays an important role in the fate determination of HSCs and MSCs in several biological process (including apoptosis, self-renewal, expansion and differentiation) (3, 4).
The factors secreted in niche including chemokines, cytokines and growth factors have significant effect on the other residing cells in the bone marrow. Induced signaling by these factors can affect the fate of stem cells and other cells (5, 6). Therefore, knowing the effective mechanisms and molecules inducing neoplastic niche can help in targeted treatment of hematological diseases.

Bone marrow is the main source of MSCs (p<0.05%). MSCs are mononuclear, adhering cells having the capacity for self-renewal, supporting hematopoiesis and the ability to differentiate into several cell lineages (e.g. chondrocytes, osteoblasts, adipocytes, dopaminergic neurons, astrocytes, tenocytes and endothelial cells) (7-10). They express specific and non-specific surface markers (Table 2). Also other identifying markers such as D7Fib, STRO-1 and SSEA exist on MSCs (11, 12). MSCs are devoid of hematopoietic and endothelial cell markers, VWF (endothelial cells marker) (13). Rat MSCs express Thy-1 and c-Kit (stem cell markers), VWF (endothelial cells marker) and a-smooth muscle actin (smooth muscle cells marker) (14).

MSCs secrete several biological factors such as anti-apoptotic factors (including vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF-1), basic fibroblast growth factor (bFGF) and granulocyte/macrophage colony stimulating factor (GM-CSF)), immunomodulatory factors (including PGE2, TGF-β, IDO, iNOS and LIF) and other factors including SCF, IL6, Angiopoietin-1, IL8 and SDF1/CXCL12, IL1, tumor necrosis factor-α (TNF-α) and bone morphogenetic proteins (BMPs) (15, 16). MSCs inhibit differentiation and activation of dendritic cells by producing PGE2, M-CSF, IL6, IL10 and TGF-β (13). Differentiation of hBMSCs into endothelial like-cells was induced in the presence of VEGF and IGF-1 (10, 17). They were also transdifferentiated into cardiomyocyte-like cells by 5-azacytidine and VEGF (18). Dexamethasone promotes the differentiation of MSCs into osteoblasts in vitro. Receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) are expressed by MSCs. Some studies have indicated that expression of OPG and RANKL respectively, is decreased and increased in MSCs with ageing (19). HSCs and MSCs synthesize BMPs. Both BMP6 and BMP2 increase osteoblastic differentiation and decrease differentiation of HSCs towards osteoclasts (20). Retinoid signaling may synergize with BMP9 activity in promoting the osteogenic differentiation of MPCs (21). Several studies have revealed that there is a balance between Wnt, FGFR and BMP signaling. Because BMP and Wnt signaling pathway lead to chondrocyte differentiation while EGF ends up to osteoblasts differentiation (22). Insulin like growth factor-1 plays a role in overexpression of CXCR4, leading to the enhancement of SDF-1 induced MSCs migration (10). Also IGFl has a role in the mesenchymal and osteoprogenitor cells recruitment and proliferation (23). MSCs exhibit the capacity to promote engraftment of CD34+ UCB cells in irradiated mice, because MSCs produce some essential hematopoietic growth factors(24). MSCs secrete dickkopf-1 (DKK-1), a Wnt signaling pathway antagonist. Wnt signaling plays a vital role in both the self-renewal and differentiation of stem cells (25). DKK-1 may act as an autocrine inhibitor.

The differentiation of MSCs into osteoblastic lineage is regulated by the BMPs and Wnt signaling (26). MSCs express RUNX2, a transcription factor that is stimulated by FGFR2 signaling and is an essential transcription factor in osteoblastogenesis (27). Wnt signaling promotes the osteoblast differentiation and function. Former studies have shown that binding of GGF to FGFR2 results in the induction of Sox2 expression, and leads to blocking the osteoblastic differentiation of MSCs and Wnt signaling. This inhibition results from the interference of Sox2 with β-Catenin and numerous other Wnt target genes such as Wisp1, Wisp2, Dlx2, and mnx2 (28, 29). Overexpression of miR-200α in Mesenchymal-like c666-1 cells inhibits β-Catenin signaling (30). TLR2, TLR4, NOD1 and NOD2 genes are expressed in hUCB-MSCs. Both NLRs and TLRs may be involved in the osteogenic differentiation of MSCs because some TLR and NLR agonists increase osteogenic differentiation of hUCB-MSCs (31). Transcription factors such as Cbfal/RUNX2, Mx2, Dlx5 and Sp7 are activated during the osteogenic differentiation of MSCs. Osteoblastic transcription factors induce the expression of bone-related marker genes including SPP1, COLIA1, SPARC and osteocalcin during the osteogenic differentiation (27). ERK phosphorylation is correlated with the osteogenic differentiation of MSCs (31). Notch maintains Mesenchymal precursor cells in an undifferentiated state. Notch1
overexpression under the control of the Prxl enhancer induced Mesenchymal precursor cells proliferation and suppresses their differentiation (26). Peroxisome proliferator-activated receptor-gamma (PPAR-γ) is a key regulator of the adipogenesis whereas hedgehog signaling inhibits adipogenesis and induces osteoblastogenesis in MSCs. IL-1, TNF-α and non-canonical Wnt signaling pathway suppress the PPAR-γ function in MSCs (32).

Table 2: The CD markers of Mesenchymal stem cells

| Marker | Name | Chromosome | Cellular expression | Role | Expression increased by | References |
|--------|------|------------|---------------------|------|-------------------------|------------|
| CD9 | Motility related protein 1 (MRP1) | 12p13.3 | B1, MZ, pre-B cell | Cell adhesion, proliferation, motility, osteoclastogenesis, metastasis suppressor, signal transduction | SDF1 | (33) |
| CD13 | Aminopeptidase N (APN) | 15q25-q26 | Myeloid cells, Fibroblasts, osteoclasts, endothelial cells, BM stromal cells, Neurons synaptic membranes | Presenting antigens, regulatory role in T cells, angiogenesis | TGFβ1, c-Maf | (34) |
| CD29 | Integrin β1 | 10p11.2 | Th17, fibroblasts, monocytes, mast cells, endothelial cells | Cell-cell and cell-matrix interaction, adhesion | | (34-38) |
| CD44 | H-CAM | 11p13 | Cell adhesion and migration, secretion and activation of MMP-2, T cell accumulation | | | (17, 33, 34) |
| CD49e | Integrin α5 (VLA-5) | 12q11-q13 | T cells, B cells, monocytes | Cell migration, development and survival, signal transduction (RTK/Ras/Erk) | | (34) |
| CD54 | ICAM1 | 19p13.3-p13.2 | Leukocytes | Inmate and adaptive immune, tumor cell growth arrest | | (33, 34) |
| CD55 | Decay-accelerating factor (DAF) | 1q32 | Many cell types (RBC, WBC) | Inhibition of complement activation | | (33) |
| CD71 | Transferrin receptor | 3q29 | Erythroid lineage | Iron uptake, Erk-MAPK signaling | | (33) |
| CD73 | 5-terminal nucleotidase | 6p14-q21 | B cells and T cells, lymphatic vessels | Prevent TRALI-induced apoptosis, suppression of pro-inflammatory process. | HIF-1 | (33, 34) |
| CD90 | Thy1 glycoprotein | 11q23.3 | Neurons, fibroblasts | Apoptotic signaling, tumor suppression, Thy1 signaling, | Iron level | (33, 35) |
| CD105 | Endoglin | 9q33-q34.1 | Endothelial cells, monocytes, | Angiogenesis, TGFβ/ALK1 signaling, anti apoptotic effect | Hypoxia, TGFβ1 | (17, 33, 34) |
| CD123 | IL3RA | Xp22.3 or Yp11.3 | Plasmacytoid dendritic cells | STAT5 and c-fos activation | | (33) |
| CD124 | IL4R | 16p12.1-p11.2 | B and T cells | IL4R signaling, immune modulation | | (33) |
| CD126 | IL6R | 1q21 | Hepatocytes, neutrophils, monocytes/macrophages, lymphocytes | Signal transduction, JAK1/TK2 and Ras activation | | (33) |
| CD127 | IL7R | 5p13 | Naïve T cells, granulosa cells, cumulus cells, preovulatory oocytes | T cell survival, upregulation of Bcl2 and Glut1 | Foxo1 | (33) |
| CD166 | ALCAM (Activated leukocyte cell adhesion molecule) | 3q13.1 | Neurons, T cells, monocytes | | | (17, 33, 34) |
| ASMA | α-smooth muscle actin | 10q23.3 | | | | (34) |
| CD271 | Low affinity nerve growth factor receptor (LNGFR) | 17q21-q22 | | | | (39) |
Hematopoietic stem cells

HSCs express markers such as CD34, CD45 and CD133 and have properties such as clonogenicity, self-renewal, and multipotentiality (40). A combination of surface markers of the signaling lymphocyte activation molecule (SLAM) family (CD150/CD48/CD41) was shown to be an HSC identifier (2). However, another study has recently shown that SLAM family markers do not permit the same degree of HSC enrichment in humans and rhesus macaques as in mice (41). Activity of osteoblasts and osteoclasts is coordinately regulated. Osteoblasts impact osteoclasts development, which is derived from HSCs (42). Osteoclasts functions are fundamental in the HSC niche (43). The factors secreted by stromal cells (e.g. heparan sulfate) have the capacity to support HSCs (44).

Notch receptors and their ligands are involved in HSCs maintenance (45). Notch1 (N1) in the murine bone marrow progenitors increases the HSC-self-renewal and immortalization of stem cells like progenitors (46). Several studies have recently shown that osteoblasts expressing the Notch ligand Jagged1 (J1) were identified as being part of the HSC niche (47, 48). Expression of the parathyroid hormone related protein (PTHrP) receptor in osteoblasts brings about increased numbers of osteoblasts to express high levels of J1 (48). Therefore, increased number of osteoblasts is accompanied with an increase in the number of HSCs, resulting in Notch1 activation in HSCs and following self-renewality of HSCs (48). These results show that J1-expressing osteoblasts regulate HSCs self-renewality through Notch1 activation. However, Manicini et al. showed that HSC's self-renewality and differentiation are independent of Jagged1-dependent Notch signaling (49).

Normal and neoplastic niche

Bone microenvironment consists of different cells such as stromal (osteoblasts, adipocytes, fibroblasts and endothelial cells) and non-stromal cells. Osteoclasts and osteoblasts have vital role in bone remodeling and niche structure (50, 51). Osteoblasts by expressing and secreting some molecules and factors regulate maturation and proliferation of other bone marrow resident cells, respectively. Osteoblasts regulate HSCs quiescence through the activation of Tie-2/Ang-1 signaling pathway (52). N-cadherin, a cell adhesion molecule, is expressed in both the osteoblasts and HSCs, suggesting that binding of N-cadherin induces the adhesion of HSCs to the niche cells (53). Studies have demonstrated that N-cad expression is down-regulated by reactive oxygen species (ROS), resulting in the release of HSCs from the niche cells. Therefore, N-cad-mediated cell adhesion has an important role in the maintaining and mobilizing of HSCs in bone marrow (54).

Osteoblasts regulate osteoclast maturation and proliferation by several factors such as RANKL (55). RANKL represents the essential osteoblast-derived factor required for osteoclast formation and activation, and induces bone loss, whereas OPG blocks these effects and prevents bone resorption (56). OPG, a member of the tumor necrosis factor receptor (TNFR) superfamily, is secreted by osteoblastic lineage cells (57), and acts as a soluble receptor antagonist for RANKL (58). The expression of RANKL and OPG by osteoblastic lineage cells is modulated by a variety of osteotropic hormones and cytokines (56).

PTH enhances osteoblast function and also increases osteoclast activity via the PTH/PTHrP receptor-1. Strontium (Sr) enhances osteoblast activity but inhibits osteoclasts by calcium sensing receptor. Sr increases the expression of Runx2, which is an essential transcription factor for osteoblastogenesis (59).

Normally, the stem cell niche maintains a balance between the quiescence and proliferation of stem cells (60). Wnt/beta-catenin growth promoting signals are counterbalanced by BMP anti-growth signals. If the dynamic balance is egregiously altered, then the dominant signalings such as Wnt/beta-catenin activation or loss of BMP can lead to cancer formation within the hematopoietic, epidermal and gastrointestinal systems (61-63).

VEGFR1-positive hematopoietic progenitors cells (HPCs) initiate the pre-metastatic niche cells. HPCs migrate from the niches within the bone marrow to the primary tumor neovasculation and pre-metastatic niche cells. Bone marrow-derived cells lie quiescent in the osteoblastic niche, but when activated, move to the vascular niche from where they egress and home to the periphery sites. At the primary tumor site, they are essential for stability of newly forming vessels, and at the pre-metastatic niche cells, angiogenic elements are required for the establishment of metastatic lesion. VEGFR1-positive HPC form clusters in these sites prior to the arrival of tumor cells (64).

Cancer stem cells (CSCs) in bone marrow reside in both the vascular and osteoblastic niches. In the vascular niche, cross-talk occurs between the CSCs and endothelial cells, while in the osteoblastic niche, CSCs interact with both the osteoclasts and osteoblasts. Within both niches, MSCs influence tumor growth and CSCs inhibit normal HSCs. Bone marrow microenvironment plays a primary...
role in the hematologic malignancy pathophysiology, and recent evidence indicates that numbers of cytokines such as leptin in multiple myeloma enhance tumor cells growth in bone marrow microenvironment (65).

Conclusion
Normal stem cells (NSCs) and CSCs are vital in tissue maintenance and malignant progression, respectively. The normal and neoplastic niches in which these cells reside play an indispensable role in NSCs and CSCs survival, proliferation, and differentiation. While the niches are each unique, there are many pathways and processes that appear to be conserved among these microenvironments. The interaction of the CSCs and the niche is a promising therapeutic target, and several drugs that affect neoplastic niche cross-talk are currently being investigated in clinical trials. Additional research is needed to further understand this complex neoplastic niche in order to fully realize the potential of this unique therapeutic target.

References
1. Abroun S, Saki N. Cellular and molecular aspects of multiple myeloma. Sci J Blood Transfus Organ. 2010; 7(3): 183-195.
2. Yin T, Li L. The stem cell niches in bone. J Clin Invest. 2006; 116(5): 1195-1201.
3. Saki N, Abroun S, Soleimani M, Kaviani S, Sadeghi B, Vaghef N. The role of myeloma cells in the in vitro differentiation of cord blood hematopoietic stem cell to osteoclast. Modares Journal of Medical Sciences: Pathobiology. 2010; 13(3): 53-61.
4. Frisch BJ, Porter RL, Calvi LM. Hematopoietic niche and bone meet. Curr Opin Support Palliat Care. 2008; 2(3): 211-217.
5. Abroun S. Chemokines in hemostasis and cancers. Yakhteh. 2008; 10(39): 155-166.
6. Sadeghi B, Abroun S, Pedrak B, Hajfathali A, Saki N, Vaghef N. The role of myeloma cells to osteoclast activation. Cell Journal (Yakhteh). 2010; 12(3): 357-366.
7. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007; 25(11): 2739-2749.
8. Westerweel PE, Verhaar MC. Directing myogenic mesenchymal stem cell differentiation. Circ Res. 2008; 103(6): 560-561.
9. Nadi S, Soleimani M, Mobarza Z, Amini S. Expression of dopamine-associated genes on conjunctiva stromal-derived human mesenchymal stem cells. Biochem Biophys Res Commun. 2008; 377(2): 423-428.
10. Jazayeri M, Allameh A, Soleimani M, Jazayeri SH, Pirzadeh A, Kazemnejad S. Molecular and ultrastructural characterization of endothelial cells differentiated from human bone marrow mesenchymal stem cells. Cell Biol Int. 2008; 32(10): 1183-1192.
11. Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Perlingeiro RC. SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood. 2007; 109(4): 1743-1751.
12. Lin G, Liu G, Banie L, Wang G, Ning H, Lue TF, et al. Tissue Distribution of Mesenchymal Stem Cell Marker Stro-1. Stem Cells Dev. 2011; 20(10): 1747-1752.
13. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007; 110(10): 3499-3506.
14. Zhang L, Chan C. Isolation and enrichment of rat mesenchymal stem cells (MSCs) and separation of single-colony derived MSCs. J Vis Exp. 2010; 37: pii: 1852. Doi: 10.3791/1852.
15. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006; 98(6): 1076-1084.
16. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009; 20(5-6): 419-427.
17. Jazayeri M, Allameh A, Soleimani M, Jazayeri SH, Kaviani S, Kazemnejad S. Capillary network formation by endothelial cells differentiated from human bone marrow mesenchymal stem cells. Iranian Journal of Biotechnology (IJB). 2008; 6(1): 29-35.
18. Nasser SM, Khaki Z, Soleimani M, Ahmadji SH, Jahanzad I, Rabbanis S, et al. The similar effect of transplantation of marrow derived mesenchymal stem cells with or without prior differentiation induction in experimental myocardial infarction. J Biomed Sci. 2007; 14(6): 745-755.
19. Bielby R, Jones E, McGonagle D. The role of mesenchymal stem cells in maintenance and repair of bone. Injury. 2007; 38(1): 26-32.
20. Vukicevic S, Grugevlic R. BMP-6 and mesenchymal stem cell differentiation. Cytokine Growth Factor Rev. 2009; 20(5-6): 441-448.
21. Zhang W, Deng ZL, Chen L, Zuo GW, Luo Q, Shi Q, et al. Retinoic acids potentiate BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. PLoS One. 2010; 5(7): e11917.
22. Miraoui H, Marie PJ. Fibroblast growth factor receptor signaling crosstalk in stemogenesis. Sci Signal. 2010; 3(146): re9.
23. Dimitriou R, Tsiridis E, Giannoudis PV. Current concepts of molecular aspects of bone healing. Injury. 2005; 36(12): 1392-1404.
24. Delalat B, Pourfathollah AA, Soleimani M, Mozdarani H, Ghaemi SR, Movassaghpour AA, et al. Isolation and ex vivo expansion of human umbilical cord blood-derived CD34+ stem cells and their cotransplantation with or without mesenchymal stem cells. Hematology. 2009; 14(3): 125-132.
25. Qiao L, Xu ZL, Zhao TJ, Ye LH, Zhang XD. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett. 2008; 269(1): 67-77.
26. Zanotti S, Canalis E. Notch and the skeleton. Mol Cell Biol. 2010; 30(4): 886-896.
27. Valentí MT, Dalle Carbonare L, Donatelli L, Bertoldo F, Zanatta M, et al. Gene expression analysis in osteoblastic differentiation from peripheral blood mesenchymal stem cells. Bone. 2008; 43(6): 1084-1092.
28. Ambrosetti D, Holmes G, Mansukhani A, Baslicio C. Fibroblast growth factor signaling uses multiple mechanisms to inhibit Wnt-induced transduction in osteoblasts. Mol Cell Biol. 2008; 28(15): 4759-4771.
29. Mansukhani A, Ambrosetti D, Holmes G, Cornivelli L, Baslicio C. Sox2 induction by FGF and FGFR2 activating mechanisms involved in the therapeutic properties of mesenchymal stem cells. Bone. 2008; 43(6): 1084-1092.
30. Ambrosetti D, Holmes G, Mansukhani A, Baslicio C. Fibroblast growth factor signaling uses multiple mechanisms to inhibit Wnt-induced transduction in osteoblasts. Mol Cell Biol. 2008; 28(15): 4759-4771.
31. Kim HS, Shin TH, YangSR, Seo MS, Kim DJ, Kang SK, et al. Implication of NOD1 and NOD2 for the differentiation of multipotent mesenchymal stem cells derived from human umbilical cord blood. PLoS One. 2010; 5(10): e15369.
Neoplastic Bone Marrow Niche

32. Takada I, Kourzenko AP, Kato S. PPAR-gamma Signaling Crosstalk in Mesenchymal Stem Cells. PPAR Res. 2010; doi: 10.1155/2010/341671.
33. Pountos I, Corscadden D, Emery P, Giannoudis PV. Mesenchymal stem cell tissue engineering: techniques for isolation, expansion and application. Injury. 2007; 38Suppl 4: S23-33.
34. Bickenbach JR. Isolation, characterization, and culture of epithelial stem cells. Methods Mol Biol. 2005; 289: 97-102.
35. Keestendijeva S, Kyrkurchev D, Tsvetkova G, Mendarjeev T, Dimitrov A, Nikolov A, et al. Characterization of mesenchymal stem cells isolated from the human umbilical cord. Cell Biol Int. 2008; 32(7): 724-732.
36. Ponzoni M, Angioni G, Gould VE, Del Curto B, Maggioni M, Scapinella A, et al. Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol. 2000; 31(2): 220-226.
37. Mahlknecht U, Schonbein C. Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells. Haematologica. 2008; 93(3): 443-446.
38. Boisvert M, Chetoui N, GendronS, Aoudjit F. Alpha2beta1 integrin is the major collagen-binding integrin expressed on human Th17 cells. Eur J Immunol. 2010; 40(10): 2710-2719.
39. Kuci S, Kuci Z, Kreyenberg H, Deak E, Putsch K, Huesneck S, et al. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lympho-hematopoietic engraftment-promoting properties. Haematologica. 2010; 95(4): 651-659.
40. Tarnok A, Urlich H, Bocsi J. Phenotypes of stem cells from diverse origin. Cytometry A. 2010; 77(1): 6-10.
41. Larochelle A, Savona M, Wiggins M, Anderson S, Iacono B, Keyvanfar K, et al. Human and rhesus macaque hematopoietic stem cells cannot be purified based only on SLAM family markers. Blood. 2011; 117(5): 1540-1549.
42. Bethel M, Srour EF, Kacena MA. Hematopoietic cell regulation of lymphocyte development and function. Curr Osteoporos Rep. 2011; 9(2): 96-102.
43. Lymeri S, Ersek A, Ferraro F, Dazzi F, Horwood NJ. Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood. 2011; 117(5): 1540-1549.
44. Bramono DS, Rider DA, Murali S, Nurcombe V, Cool SM. The effect of human bone marrow stroma-derived heparan sulfate on the ex vivo expansion of human cord blood hematopoietic progenitors. Biologics. 2011; 4(2): 1395-1394.
45. Radtke F, Wilson A, Mancini SJ, MacDonald HR. Notch regulation of lymphocyte development and function. Nat Immunol. 2004; 5(3): 247-253.
46. Stier S, Cheng T, Dombkowski D, Carlesso N, Scadden DT. Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. Blood. 2002; 99(7): 2369-2378.
47. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, et al. Identification of the hematopoietic stem cell niche and control of the niche size. Nature. 2003; 425(6960): 836-841.
48. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, et al. Osteoblastic cells regulate the hematopoietic stem cell niche. Nature. 2003; 425(6960): 841-846.
49. Mancini SJ, Mantel N, Dumortier A, Suter U. MacDonald HR, Radtke F. Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation. Blood. 2005; 105(6): 2340-2342.
50. Dazzi F, Ramasamy R, Glemnis S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev. 2006; 20(3): 161-171.
51. Roedman GD. Regulation of osteoclast differentiation. Ann N Y Acad Sci. 2006; 1068: 100-109.
52. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell. 2004; 118(2): 149-161.
53. Kiel MJ, Radice GL, Morrison SJ. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. Cell Stem Cell. 2007; 1(2): 204-217.
54. Hosokawa K, Arai F, Yoshihara H, Nakamura Y, Gomei Y, Iwasaki H, et al. Function of oxidative stress in the regulation of hematopoietic stem cell-niche interaction. Biochem Biophys Res Commun. 2007; 363(2): 578-583.
55. Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K, et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor RANKL but not macrophage colony-stimulating factor receptor activator of NF-kappa B ligand. Bone. 1999; 25(5): 517-523.
56. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000; 289(5484): 1504-1508.
57. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2): 309-319.
58. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2): 165-176.
59. Lymeri S, Horwood N, Marley S, Gordon MY, Cope AP, Dazzi F. Strontium can increase some osteoblasts without osteoprogenitor cells. Blood. 2008; 111(3): 1173-1181.
60. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006; 66(9): 4553-4557.
61. Haramis AP, Begthel H, van den Born M, van Es J, Jonkheer S, Offerhaus GJ, et al. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science. 2004; 12; 303(5684): 1684-1686.
62. He XC, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH, et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat Genet. 2004; 36(10): 1117-1121.
63. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Kater L, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; 351(7): 657-667.
64. Kaplan RN, Riba RD, Charachoulis S, Bramley AH, Vincent, S, Sadeghi B, et al. The role of Leptin in pathophysiology of myeloma cells. Cell Journal (Yakhteh). 2010; 12(3): 651-659.